RhumbLine Advisers
MREO

RhumbLine Advisers’s Mereo BioPharma MREO Stock Holding History

RhumbLine Advisers’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.51K Buy
26,784
+7,212
+37% +$2.16K ﹤0.01% 3923
2026
Q1 		$6.45K Buy
19,572
+426
+2% +$183 ﹤0.01% 3852
2025
Q4 		$7.98K Buy
19,146
+10,024
+110% +$19.1K ﹤0.01% 3882
2025
Q3 		$18.8K Sell
9,122
-756
-8% -$1.39K ﹤0.01% 3787
2025
Q2 		$26.8K Buy
9,878
+3,290
+50% +$7.94K ﹤0.01% 3766
2025
Q1 		$14.8K Sell
6,588
-649
-9% -$1.84K ﹤0.01% 3779
2024
Q4 		$25.3K Sell
7,237
-36
-0.5% -$141 ﹤0.01% 3771
2024
Q3 		$29.9K Buy
7,273
+315
+5% +$1.3K ﹤0.01% 3759
2024
Q2 		$25K Buy
6,958
+2,887
+71% +$9.35K ﹤0.01% 3831
2024
Q1 		$13.4K Buy
4,071
+162
+4% +$548 ﹤0.01% 3821
2023
Q4 		$9.03K Buy
3,909
+311
+9% +$595 ﹤0.01% 3882
2023
Q3 		$4.64K Buy
3,598
+340
+10% +$451 ﹤0.01% 3992
2023
Q2 		$4.3K Buy
+3,258
New +$3.78K ﹤0.01% 4116

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

RhumbLine Advisers's MREO Position: Q2 2026 in Review

RhumbLine Advisers increased its Mereo BioPharma (MREO) stake by 37% in Q2 2026, buying an estimated $2.16K and bringing the position to 26,784 shares worth $8.51K. The position accounts for ﹤0.01% of the portfolio, ranked #3923.

RhumbLine Advisers first reported a position in MREO in Q2 2023 and has held it in 13 quarters since. The position peaked at $29.9K in Q3 2024. 60 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

  • RhumbLine Advisers held 26,784 shares of Mereo BioPharma worth $8.51K as of Q2 2026.
  • RhumbLine Advisers bought 7,212 Mereo BioPharma shares in Q2 2026, an estimated $2.16K.
  • Mereo BioPharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3923 holding.
  • RhumbLine Advisers first reported a position in Mereo BioPharma in Q2 2023 and has held it in 13 quarters since.
  • RhumbLine Advisers's Mereo BioPharma position peaked at $29.9K in Q3 2024.
  • 60 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.